Clinical Trials

110 enrolled

Other solid neoplasm

Advanced Solid Tumour

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07039162 2026-02-27

Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT07136077 2026-02-27

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Colorectal Neoplasms, Neoplasm, Residual

NCT07418190 2026-02-18

Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma

33 enrolled

Lymphoid

Lymphoma, Follicular

NCT07413354 2026-02-17

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

94 enrolled

Carcinoma, Hepatocellular

NCT07370337 2026-01-27

Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal

50 enrolled

Squamous Cell Carcinoma of External Auditory Canal

NCT07330037 2026-01-09

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

41 enrolled

NSCLC

NCT06877299 2026-01-02

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06722183 2025-12-24

FUTURE

33 enrolled

Colorectal Neoplasms

NCT07296705 2025-12-22

HARBOR

25 enrolled

Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

NCT03736889 2025-12-17

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

200 enrolled

Other solid neoplasm

MSI-H/dMMR Solid Tumors

NCT05977673 2025-12-08

FIL_Tisle-HL

28 enrolled

Lymphoid

Hodgkin Disease, Lymphoma

NCT07264647 2025-12-04

Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT07233252 2025-11-18

Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer

35 enrolled

Genitourinary

Renal Pelvic Carcinoma

NCT06529523 2025-10-07

Tislelizumab in People With Colorectal Cancer

40 enrolled

Colorectal Neoplasms

NCT06838208 2025-09-24

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

56 enrolled

Small Cell Lung Carcinoma

NCT06884670 2025-09-08

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

130 enrolled

Rectal Neoplasms

NCT05758389 2025-09-05

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

29 enrolled

Head & Neck

Head and Neck Neoplasms

NCT07086456 2025-07-25

Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer

80 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06379087 2025-07-10

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Carcinoma, Non-Small-Cell Lung

NCT07047586 2025-07-03

LEAF-01

146 enrolled

Carcinoma, Hepatocellular

NCT06446726 2025-06-06

Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

NCT06157996 2025-05-30

Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore

92 enrolled

Stomach Neoplasms

NCT06659042 2025-05-18

Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06420440 2025-05-01

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

160 enrolled

Carcinoma, Hepatocellular, Recurrence

NCT06939127 2025-04-22

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06673693 2025-04-16

NEOSTART

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06897579 2025-04-11

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

134 enrolled

Extensive Stage Small Cell Lung Cancer

NCT06881537 2025-03-18

CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer

15 enrolled

Locally Recurrent Colorectal Cancer

NCT04954781 2025-02-27

TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma

25 enrolled

Cholangiocarcinoma

NCT06032845 2025-02-27

CASTLE-11

25 enrolled

Other solid neoplasm

Solid Tumor, Adult

NCT06829355 2025-02-17

THYMI

52 enrolled

MCRC

NCT05920863 2025-02-11

Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors

35 enrolled

Carcinoma, Hepatocellular

NCT05532059 2025-02-10

Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma

100 enrolled

Cholangiocarcinoma

NCT04615143 2025-01-09

TALENT

80 enrolled

Carcinoma, Hepatocellular

NCT06749860 2024-12-27

Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression

58 enrolled

Lung Neoplasms

NCT06749886 2024-12-27

An Exploratory Study of Tislelizumab in Combination with Chemotherapy in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the Second-line Setting

22 enrolled

Lung Neoplasms

NCT05758116 2024-11-26

Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Carcinoma, Non-Small-Cell Lung

NCT06538896 2024-11-26

Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study

Breast

Triple Negative Breast Neoplasms

NCT05468242 2024-10-30

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

116 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06646588 2024-10-17

SJZ-RMEEC01

67 enrolled

Esophageal Neoplasms

NCT06353360 2024-08-09

TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

CNS

Glioblastoma

NCT06536868 2024-08-05

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

40 enrolled

Small Cell Lung Carcinoma

NCT06354140 2024-07-17

PPIO-008 Tislelizumab Combined With S-1 in Patients With ypT+N0 ESCC After Radical Resection With Neoadjuvant STUDY

45 enrolled

Esophageal Squamous Cell Carcinoma

NCT05531123 2024-07-12

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Genitourinary

Urinary Bladder Neoplasms

NCT06451211 2024-06-11

Neo-ICEBOAT

53 enrolled

Stomach Neoplasms

NCT04799548 2024-05-23

A Phase II Study of TACE Plus PD-1 Antibody in the Locally Advanced Stomach Adenocarcinoma

71 enrolled